Published in Neurology on June 14, 2013
Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain (2014) 5.12
Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease. Parkinsonism Relat Disord (2015) 0.77
Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet (2012) 3.80
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain (2013) 2.40
MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology (2014) 2.14
Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov Disord (2012) 1.98
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol (2008) 1.96
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 1.94
Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol (2006) 1.86
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord (2007) 1.85
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord (2007) 1.72
Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur J Hum Genet (2005) 1.71
Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am J Hum Genet (2004) 1.66
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord (2013) 1.62
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest (2014) 1.58
Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology (2009) 1.56
Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord (2006) 1.50
The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. Mov Disord (2008) 1.43
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis (2010) 1.41
Affective theory of mind in patients with Parkinson's disease. Psychiatry Clin Neurosci (2013) 1.41
Diagnosis, assessment and management of delusional jealousy in Parkinson's disease with and without dementia. Neurol Sci (2012) 1.39
High-power microscopy for selecting spermatozoa for ICSI by physiological status. Reprod Biomed Online (2008) 1.34
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord (2011) 1.21
Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.20
Clinical features associated with ictal osmophobia in migraine. Neurol Sci (2014) 1.19
Myoclonus-dystonia syndrome: clinical presentation, disease course, and genetic features in 11 families. Mov Disord (2008) 1.15
Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations. Mol Genet Metab (2011) 1.13
Mutation screening of the DYT6/THAP1 gene in Italy. Mov Disord (2009) 1.11
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica (2011) 1.10
Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. Mov Disord (2011) 1.08
A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome. Mov Disord (2008) 1.06
PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum Mutat (2008) 1.06
Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain (2013) 1.05
Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism Relat Disord (2011) 1.04
Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early Parkinson's disease. J Clin Neurophysiol (2003) 1.03
Dopaminergic modulation of visual-spatial working memory in Parkinson's disease. Dement Geriatr Cogn Disord (2003) 1.00
IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients. Autism Res Treat (2012) 0.97
Personality traits in patients with Parkinson's disease: assessment and clinical implications. J Neurol (2011) 0.96
Telethon Network of Genetic Biobanks: a key service for diagnosis and research on rare diseases. Orphanet J Rare Dis (2013) 0.96
Theory of Mind in Parkinson's disease. Behav Brain Res (2011) 0.94
Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord (2009) 0.94
Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood (2002) 0.93
C19orf12 and FA2H mutations are rare in Italian patients with neurodegeneration with brain iron accumulation. Semin Pediatr Neurol (2012) 0.93
Reduced endothelial progenitor cell number and function in inflammatory bowel disease: a possible link to the pathogenesis. Am J Gastroenterol (2009) 0.93
Decision making in de novo Parkinson's disease. Mov Disord (2010) 0.92
Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat (2004) 0.92
Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. Ther Adv Psychopharmacol (2013) 0.92
Cerebellar ataxia with complete clinical recovery and resolution of MRI lesions related to central pontine myelinolysis: case report and literature review. Case Rep Neurol (2010) 0.90
Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study. Mov Disord (2008) 0.90
Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 cases. Neuropediatrics (2012) 0.90
Activity-based diary for Parkinson's disease. Clin Neuropharmacol (2002) 0.90
Early-onset neurodegeneration with brain iron accumulation due to PANK2 mutation. Brain Dev (2011) 0.90
Progression of brain atrophy in the early stages of Parkinson's disease: a longitudinal tensor-based morphometry study in de novo patients without cognitive impairment. Hum Brain Mapp (2014) 0.90
Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin Neuropharmacol (2004) 0.90
Parkin analysis in early onset Parkinson's disease. Parkinsonism Relat Disord (2007) 0.89
Variant late infantile ceroid lipofuscinoses associated with novel mutations in CLN6. Biochem Biophys Res Commun (2009) 0.89
The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. J Clin Exp Neuropsychol (2012) 0.89
A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol (2013) 0.89
Case-control study of multiple system atrophy. Mov Disord (2005) 0.88
Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet (2003) 0.88
Affective symptoms and cognitive functions in Parkinson's disease. J Neurol Sci (2012) 0.87
Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy. Orphanet J Rare Dis (2013) 0.86
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. Neuropsychiatr Dis Treat (2008) 0.86
Skin fibroblasts from pantothenate kinase-associated neurodegeneration patients show altered cellular oxidative status and have defective iron-handling properties. Hum Mol Genet (2012) 0.86
Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov Disord (2009) 0.86
Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome. Neurol Sci (2013) 0.86
Human L-ferritin deficiency is characterized by idiopathic generalized seizures and atypical restless leg syndrome. J Exp Med (2013) 0.86
Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Funct Neurol (2013) 0.85
Bilateral thalamic infarct caused by spontaneous vertebral artery dissection in pre-eclampsia with HELLP syndrome: a previously unreported association. J Stroke Cerebrovasc Dis (2012) 0.85
Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS One (2011) 0.85
Decreased and increased cortical activation coexist in de novo Parkinson's disease. Exp Neurol (2010) 0.84
Iowa gambling task in Parkinson's disease. J Clin Exp Neuropsychol (2010) 0.84
Multiplex ligation-dependent probe amplification assay for simultaneous detection of Parkinson's disease gene rearrangements. Mov Disord (2007) 0.84
Abnormal response to photic stimulation in juvenile myoclonic epilepsy: an EEG-fMRI study. Epilepsia (2014) 0.84
Treatment of patients with tardive dystonia with olanzapine. Clin Neuropharmacol (2002) 0.84
Hypoactivation of the primary sensorimotor cortex in de novo Parkinson's disease : a motor fMRI study under controlled conditions. Neuroradiology (2011) 0.84
Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. J Neurol (2012) 0.83
A Novel Homozygous YARS2 Mutation in Two Italian Siblings and a Review of Literature. JIMD Rep (2015) 0.83
Parkinson's disease and pathological gambling: results from a functional MRI study. Mov Disord (2010) 0.83
Barth syndrome presenting with acute metabolic decompensation in the neonatal period. J Inherit Metab Dis (2006) 0.83
Levodopa response in dementia with lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord (2010) 0.83
Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in patients with Parkinson's disease after levodopa loading. Clin Neuropharmacol (2002) 0.83
Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. J Neurol (2010) 0.82
Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. Parkinsonism Relat Disord (2013) 0.82
A novel mutation in the SURF1 gene in a child with Leigh disease, peripheral neuropathy, and cytochrome-c oxidase deficiency. J Child Neurol (2002) 0.82
How aware are migraineurs of their triggers? Headache (2013) 0.82
Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study. Mov Disord (2007) 0.82
Postpartum headache due to spontaneous cervical artery dissection. Headache (2011) 0.82
Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients. Parkinsonism Relat Disord (2011) 0.82
Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. Mov Disord (2005) 0.82
Mapping cortical degeneration in ALS with magnetization transfer ratio and voxel-based morphometry. PLoS One (2013) 0.81
Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease. Curr Neurovasc Res (2013) 0.81
Levetiracetam-responsive myoclonus in spinocerebellar ataxia type 15. Mov Disord (2013) 0.81
Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. Mov Disord (2006) 0.81